PG545 (pixatimod) in combination with nivolumab

Estado del programa

Reclutamiento

Fase

Fase 1

Inmunoterapia previa permitida

Ensayo dirigido por el CRC

Etiquetas

MSI-H/ MMRd, MSS/ MMRp

Comentarios

Trial with preliminar good result in CRC, only in Australia.
Nov 2018: “Of the 5 subjects evaluable for assessment of anti-tumour activity, one with microsatellite stable (MSS) mCRC had a partial response (PR) with an 86% reduction in the size of target lesions at the 26-week scan”

NCT ID

PG545 (pixatimod) in combination with nivolumab

Fecha en que se añadió el juicio

2019-04-26

Fecha de actualización

2019-07-29